Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and ...

Receding floodwaters that submerged homes days before left the residents of Mthatha, South Africa, helpless. They watched the bodies of their families and ...

Authorities in Kenya have arrested a senior police officer responsible for the cell where a blogger died, leading to ...

The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...